Arrowhead Pharmaceuticals vs Nurix Therapeutics
Arrowhead Pharmaceuticals is the larger business, with $829m of revenue in fiscal 2025 against $84.0m for Nurix Therapeutics (9.9 times as much). Arrowhead Pharmaceuticals grew faster (23258.2% against 54.0%). Arrowhead Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -0.2% against -314.9%.
| Latest fiscal year | Arrowhead PharmaceuticalsARWR, 2025 | Nurix TherapeuticsNRIX, 2025 |
|---|---|---|
| Revenue | $829m | $84.0m |
| Revenue growth | 23258.2% | 54.0% |
| Net income | −$1.6m | −$264m |
| Operating margin | — | -340.2% |
| Net margin | -0.2% | -314.9% |
| Return on equity | -0.5% | -49.6% |
| Free cash flow | $157m | −$263m |
| Cash | $227m | $247m |
| Total debt | $255m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 711 | 317 |
| Market value | $8.43bn | $2.81bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 64 sales | 0 buys, 44 sales |